Wednesday, April 25, 2012

Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company

Acquisition Will Build on Amgen’s Existing Business and Provide a Platform for Growth in Turkey and This Strategically Important Region

THOUSAND OAKS, Calif. and ISTANBUL, April 25, 2012 /PRNewswire via COMTEX/ --Amgen (NASDAQ:AMGN), the world’s largest biotechnology company, and Mustafa Nevzat Pharmaceuticals (MN) today announced an agreement under which Amgen will acquire 95.6 percent of shares in MN, a privately held Turkish pharmaceutical company, for an amount that values MN at US $700 million.  The all-cash transaction will significantly expand Amgen’s presence in Turkey and the surrounding region, which are large, fast-growing, priority markets for Amgen.

Read the rest of this entry

Posted in Press Releases

Monday, April 23, 2012

A Tribute to George Rathmann, Amgen's Founding CEO (1927-2012)

THOUSAND OAKS, Calif., April 23, 2012 /PRNewswire via COMTEX/ --Amgen (NASDAQ:AMGN) today announced that George Rathmann, founding CEO of Amgen from 1980 to 1988 and board chairman until 1990, has passed away.

Read the rest of this entry

Posted in Press Releases

Thursday, April 19, 2012

Amgen Announces Webcast of 2012 First Quarter Financial Results

THOUSAND OAKS, Calif., April 19, 2012 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced that it will report its first quarter financial results on Tuesday, April 24, 2012, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m.  Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and CEO, and other members of Amgen’s senior management team.

Read the rest of this entry

Posted in Press Releases

Tuesday, April 10, 2012

Amgen to Acquire Privately Held KAI Pharmaceuticals

Acquisition Includes KAI-4169 Program, Which Delivered Compelling Phase 2a Clinical Results for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease who are on Dialysis

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., April 10, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco.  KAI’s lead product candidate, KAI-4169, is a novel agent being initially studied for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis.  SHPT, a component of CKD mineral and bone disorder (MBD), is a common and serious complication for patients with CKD who are on dialysis.  Through this acquisition, Amgen will acquire worldwide rights, excluding Japan, to KAI-4169.

Read the rest of this entry

Posted in Press Releases

Tuesday, April 03, 2012

UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis

First Patient Randomized Marks Start of Phase 3 Program to Evaluate Safety and Efficacy of CDP7851/AMG 785 in Women With Postmenopausal Osteoporosis

BRUSSELS and THOUSAND OAKS, Calif., April 4, 2012 /PRNewswire/ -- UCB (Euronext Brussels: UCB) and Amgen (NASDAQ:AMGN) announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis.

Read the rest of this entry

Posted in Press Releases